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Abstract—SARS-CoV-2 is a severe respiratory infection that 
infects humans. Its outburst entitled it as a pandemic emergence. 
To get a grip on this, outbreak specific preventive and therapeutic 
interventions are urgently needed. It must be said that, until now, 
there are no existing vaccines for coronaviruses. To promptly and 
rapidly respond to pandemic events, the application of in silico 
trials can be used for designing and testing medicines against 
SARS-CoV-2 and speed-up the vaccine discovery pipeline, 
predicting any therapeutic failure and minimizing undesired 
effects. Here, we present an in silico platform that showed to be in 
very good agreement with the latest literature in predicting SARS-
CoV-2 dynamics and related immune system host response. 
Moreover, it has been used to predict the outcome of one of the 
latest suggested approach to design an effective vaccine, based on 
monoclonal antibody. UISS is then potentially ready to be used as 
an in silico trial platform to predict the outcome of vaccination 
strategy against SARS-CoV-2. 
 
Index Terms—Agent-Based Model, human monoclonal 
antibodies, In Silico Trials, SARS-CoV-2, vaccines.  
 
I. INTRODUCTION 
 
s the epicenter of Coronavirus disease 2019 (COVID-19) 
and emerging severe acute respiratory syndrome (SARS) 
caused by novel Coronavirus (2019-nCoV) spread is making its 
way across the world, global healthcare finds itself facing 
tremendous challenges. According to the World Health 
Organization (WHO) situation report (91st), updated on 20 
April 2020, there have been globally 72846 confirmed cases of 
2019-nCoV and 5296 cases of death caused by the virus itself 
[1].  
2019-nCoV (also referred to as SARS-CoV-2 or HCoV-19) 
[2], is the seventh coronavirus known to infect humans along 
with SARS-CoV, MERS-CoV, HKU1, NL63, OC43 and 229E 
[3]. While these last four coronaviruses are associated with mild 
symptoms, SARS-CoV, MERS-CoV and SARS-CoV-2 can 
cause severe acute respiratory syndrome [4], especially in 
elderlies, of which men, and those individuals with 
comorbidities and immunocompromised conditions [5]). 
Although it is similar to SARS-CoV, SARS-CoV-2 has an 
improved ability for pathogenicity [6]. In particular, latest 
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evidences during the ongoing pandemic reveal that patients 
affected by SARS-CoV-2 can progress their clinical picture 
from fever, cough, ageusia and anosmia, sore throat, 
breathlessness, fatigue, or malaise to pneumonia, acute 
respiratory distress syndrome (ARDS) and multi organ 
dysfunction illness [7]. Significantly, in most critically ill 
patients, SARS-CoV-2 infection is also associated with a severe 
clinical inflammatory picture based on a serious cytokine storm 
that is mainly characterized by elevated plasma concentrations 
of interleukins 6 (IL-6) [8]. In this scenario, it seems that IL-6 
owns an important driving role on the cytokine storm, leading 
to lung damage and reduced survival [9].  
To get a grip on this outbreak and flatten the curve of 
infection, a specific therapeutic intervention to prevent the 
severity of the disease is urgently needed to reduce morbidity 
and mortality because, until now, there are no existing vaccines 
for coronaviruses. 
The ideal profile for a targeted SARS-CoV-2 vaccine must 
address the need of vaccinating human population, with 
particular regard of those individuals classified as at high risk, 
comprising, for example, frontline healthcare workers, 
individuals over the age of 60 and those that show debilitating 
chronic diseases.  
Recently, specific findings about the genome sequencing of 
SARS-CoV-2 in different countries where cases of infection 
were registered, revealed its relative intrinsic genomic 
variability, its virus dynamics and the related host response 
mechanisms, unveiling interesting knowledge useful for the 
formulation of innovative strategies for preventive vaccination.  
Specifically, SARS-CoV-2 sequencing along with its relative 
intrinsic genomic variability [10], the presence of minority 
variants generated during SARS-CoV-2 replication [11], the 
involved cellular factors that favors SARS-CoV-2 cell entry 
[12], the timing in which viral load peaks (during the first week 
of illness), its gradual decline (over the second week) and the 
increasing of both IgG and IgM antibodies (around day 10 after 
symptom onset) represent some of the relevant insights so far 
delineated and considered by research community about SARS-
CoV-2 virus [13].  
Even though these findings are having several practice 
consequences and suggest valuable conclusions, SARS-CoV-2 
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dynamics has not been yet fully understood. Information about 
which parts of SARS-CoV-2 sequence are recognized by the 
human immune system is still limited and scarcely available. 
Such knowledge would be of immediate relevance and great 
help for the design of new vaccines, facilitating the evaluation 
of potential immunogenic candidates, as well as monitoring the 
virus mutation events that would be transmitted through the 
human population.  
Currently, there are at least 42 vaccine candidates around the 
world under development and evaluation at different stages 
against COVID-19 [14], also accordingly from what reported 
by WHO through its continuously undergoing landscapes 
documents concerning the COVID-19 candidate vaccines. 
These promising vaccine candidates deal with several vaccine 
technologies based on recombinant protein subunits [15], 
nucleic acids [16], non-replicating and replicating viral vectors 
[17], [18], protein constructs [19], virus-like particles [20], live-
attenuated virus strains [21], inactivated virus [14], or human 
monoclonal antibodies (mAbs) [22].  
Today, challenges of continuing development of solutions 
for COVID-19 pandemic are a mandatory need. As never 
before, the application of modeling and simulation can actively 
design better vaccine prototypes, support decision making, 
decrease experimental costs and time, and eventually improve 
success rates of the trials. To this aim, in silico trials (ISTs) for 
design and testing medicines [23]–[25] can accelerate and 
speed-up the vaccine discovery pipeline, predicting any 
therapeutic failure and minimizing undesired effects. 
Beyond traditional modeling techniques or applications, 
Agent-Based Models (ABMs) represent a paradigm that can 
cover the entire spectrum of the vaccine development process 
[26], especially for the quantification and prediction of the 
humoral and cellular response of a specific candidate vaccine 
as well as its efficacy [27]. 
The simulation platform we use from fifteen years, named 
Universal Immune System Simulator (UISS), is based on agent-
based methodology, which is able to brilliantly simulate each 
single entity of the immune system (and consequently its 
dynamics), along with the significant immune responses 
induced by a specific pathogen or stimulus. Recently, UISS 
provided different success stories in immunology field as it is 
most widely reported in the literature [28]–[31]. 
We chose to analyze, within the wide landscape of potential 
candidate vaccines against SARS-CoV-2, a specific cross-
neutralizing antibody that Wang et al. [32] suggest to be 
promising in targeting and binding a communal conserved 
epitope of SARS-CoV-2 and SARS-CoV on the spike receptor 
binding domain [33], through an independent mechanism of 
receptor binding inhibition. 
As a case study, here we report a first application of UISS in 
silico platform to provide predictions of the efficacy of a 
potential therapy against COVID-19 based on a mAb strategy 
intervention like the one proposed by Wang et al. 
II. METHODOLOGY 
A. Introduction to Agent-Based Models and UISS, an in silico 
platform for the human immune system simulation 
Agent-Based Models (ABMs) belong to the class of 
mechanistic models, a family of models that, differently from 
data-driven models, uses a description of the underlying 
mechanisms of a given phenomenon to reproduce it.  Such a 
description is usually based on different observational data, 
previous knowledge and/or hypotheses, and is usually 
aggregated and rationalized into a conceptual map (i.e., a flow 
chart and/or a schematic disease model) that reassumes the 
cascade of events of the phenomenon under investigation.  The 
conceptual map is then translated into 
mathematical/computational terms and then executed by 
computers to observe, in silico, the evolution of the 
phenomenon over time. Besides ABMs, other modeling 
techniques based on the mechanistic approach can be used. 
Among these, we recall, for example, ordinary and partial 
differential equations [34]–[36] and Petri nets [37], [38]. 
As the name suggests, agent-based models are based on the 
paradigm of ‘agents’, autonomous entities that behave 
individually according to established rules. Such entities can be 
heterogeneous in nature, and are usually represented on a 
simulation space where they are free to move, interact each-
other and change their internal state as a consequence of 
interactions. From a computer science perspective, agents can 
be seen as stochastic finite-state machines, capable of assuming 
a limited number of discrete states. Using ABMs, the global 
evolution of the phenomena is observed by taking into account 
the sum of the individual behaviors of all agents, and sometimes 
unexpected “emergent” behaviors may be observed.  
ABMs have been successfully applied in many research 
fields, from social sciences to ecology, from epidemiology to 
biology.  In the field of immunology, we developed the 
Universal Immune System Simulator (UISS), an agent-based 
framework that has been extended through the last decades to 
simulate the behavior of the immune system response when 
challenged against many diseases.  
In UISS agents are used to describe cells and molecules of 
the immune system, as well as external actors that can 
destabilize (i.e., pathogens such as viruses and bacteria) or 
restore (i.e. prophylactic and therapeutic treatments) the normal 
health of the host. 
One of the main features of UISS is its ability to mimic the 
adaptive immune response mechanisms. Mammals have in fact 
developed an advanced immune system machinery capable to 
specifically recognize pathogens in order to better react against 
them. This advanced response is based on the ability to exactly 
recognize foreign proteins (i.e., epitopes) on pathogens surface 
by means of receptors, through a key-to-lock mechanism. 
While an explicit implementation would be both unfeasible and 
partially inaccurate from a computational point of view, in 
UISS we mimic such a process through the use of binary strings. 
Binary strings are used for both representing epitopes and 
immune system cells’ receptors, and the probability that an 
immune system cell recognizes a pathogen is proportional to 
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the Hamming distance (the number of mismatching bits) 
between the two strings involved into the interaction. Although 
this abstraction may seem binding, millions of interactions can 
be simulated quickly on modern computers, making easier the 
reproduction of many features of the immune system such as 
memory, specificity, tolerance and homeostasis. For example, 
this abstraction demonstrated able to allow the selection of the 
best adjuvant among a series of candidates for an influenza 
vaccine when properly coupled with results coming from 
existing binding prediction tools [28]. This suggests how such 
an abstraction is able to capture the complexity of the problem.  
Besides of receptors, UISS implements many other immune 
system mechanisms, as thymus selection, haematopoiesis, cell 
maturation, Hayflick limit, aging, immunological memory, 
antibody hyper-mutation, bystander effect, cell anergy, antigen 
processing and presentation. 
Up to now, UISS in silico platform has been successfully 
applied to the design and verification of novel treatments for 
many diseases in both preclinical and clinical environments, 
including pathologies such as mammary carcinoma [39] and 
derived lung metastases [40] , melanoma [41], atherosclerosis 
[42], multiple sclerosis [31] and influenza [28].  
More recently, UISS has been used as the centerpiece of the 
StriTuVaD H2020 project with the aim to create an in silico trial 
for tuberculosis. In this context, observations from virtual 
patients will be coupled with results from a real clinical trial to 
obtain an in silico augmented clinical trial, with greater 
accuracy and more statistical power [30]. 
B. SARS-CoV-2 disease model 
The SARS-CoV-2 disease model has been implemented in 
UISS computational framework starting by identifying a 
question of interest.  The question of interest describes the 
specific question, decision or concern that is being addressed 
with a computational model. In other words, the question of 
interest lays out the engineering question that is to be answered 
(at least in part) through a model. The next step is to define the 
context of use (CoU), which provides a detailed and complete 
explanation of how the computational model output will be 
used to answer the question of interest. In this specific study, 
the question of interest is how potential prophylactic or 
therapeutic vaccines could cure COVID-19, building or 
stimulating an effective immune response against SARS-CoV-
2 virus. UISS must then represent and reproduce the 
fundamental SARS-CoV-2 – immune system competition and 
dynamics. To this end, we first selected all the players that have 
a role in the viral infection both at cellular and molecular scale 
and then we categorized all the interactions among entities that 
play a relevant role in this biological scenario. Finally 
compartment assumptions have to be done to let the entities 
move and interact each other. In our case, we considered the 
lung compartment that models the main organ target of the virus 
and the generic lymph node that allows immune system entities 
to be activated and selected. Figure 1 gives a detailed sketch on 
the main compartments, entities and interactions.  
SARS-CoV-2 first entry is located in the upper respiratory tract. 
Then it proceeds to bronchial and finally to lungs in which it 
reaches its main cellular target i.e., the epithelial lung cells 
(LEP) [43]. The virus is eventually captured by dendritic cells 
(DC) and macrophages (M). DC are the main antigen 
processing cells of the immune system [44] that are able to 
present the peptides antigen complexed in both major 
histocompatibility class I and class II (MHC-I and MHC-II, 
respectively). If a DC encounters the native virus form, it can 
be able to process it and present its peptides complexed with 
MHC-II to CD4 T cells for further actions. DC, upon virus 
activation, release interferon type A and B (IFN-A and IFN-B) 
and interleukin-12 (IL-12) that are important cytokines in 
fighting intracellular pathogens. Also, M are able to capture the 
native form of the SARS-CoV-2 and, if properly activated by 
pro-inflammatory cytokines, be able to internally destroy it. 
After their successful activation, macrophages release a pro-
inflammatory cytokine that is tumor necrosis factor alpha 
(TNF-alpha). A fraction of SARS-CoV-2 viruses reach LEP 
and through the envelope spike glycoprotein binds to their 
cellular receptor, ACE2. Doing that, the viral RNA genome 
starts to be released into the cytoplasm and is translated into two 
polyproteins and structural proteins, after which the viral 
genome begins to replicate inside the cell [45]. Following the 
flux of the conceptual disease model represented in Figure 1, 
after a certain amount of time (that we tuned with available data, 
as described in the next sections), new copies of the virus are 
released from the infected LEP that eventually dies. New 
released copies of functional SARS-CoV-2 infect new cells, 
spreading further the infection in the lungs. When a cell is 
infected by a virus, it can be susceptible of different destinies. 
One of them is the shutting down of MHC-I expression to avoid 
 
 
Fig. 1.  SARS-CoV-2 disease model implemented in UISS. Main 
compartments (lung, and lymph-nodes) are delimited with dashed lines. 
Peripheral blood compartment is seen as connecting duct, not explicitly 
represented. The starting point is the SARS-CoV-2 droplets entrance in the 
upper respiratory tract (not shown). Then, all the main infection dynamics is 
described. The immune system cascade is shown as it was implemented, based 
on the latest research results published in specialized literature. For each 
entity, the localization (i.e., the biological compartment in which the entities 
are present) and the status (i.e., the differentiation states that an entity can own) 
are defined. The results of the immune system mounting process is the killing 
of the infected lung epithelial cells by the cytotoxic T lymphocyte and the local 
release of both chemokine factors and cytokines. At the humoral level, specific 
IgM (first) and IgG (after) directed against SARS-CoV-2 virus are released by 
plasma B cells. Regulatory system is also involved in the process. If the 
immune system machinery works correctly, regulatory arm shutdowns 
excessive cytokines storm, avoiding the severe prognosis of COVID-19. 
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immune system recognition from specific CD8 T cells. In this 
case, a population of innate immunity cells, natural killer cells 
(NK) may identify them and proceed to kill them through 
specific actions. The other one is represented by a different 
MHC-I presentation on the cell surface, as the virus has 
modified the normal behavior of cell to let the host to make 
functioning virus copies. In this circumstance, (that we 
supposed to happen during SARS-CoV-2 infection) cell MHC-
I presentation is different from the normal case. DC are able 
(through a mechanism known as “nibbling” process [46]) to 
cross present the antigen complexed with MHC-I proteins to let 
adaptive immune response to recognize and kill virus infected 
cells. Activated and antigen presenting cells (both DC and/or 
M) migrate into the proximal lymph nodes to present their 
content to adaptive immune cells i.e., T cells and B cells. Also, 
a portion of viruses could eventually migrate to the lymph 
nodes. Here, B cells can be activated by virus if specific 
immunoglobulin receptor in B cell surface binds to it. In this 
context, B cell is activated, and it immediately releases 
immunoglobulins of M class (IgM) that are the first antibody 
response that can be measured. Further, APC cells activate CD4 
T cells (helper T cells, Th) that under the influence of specific 
cytokines released before, differentiate into helper T cell type 1 
(Th1). Th1 migrate under chemokines gradient to the site of 
infection. There, they release interferon gamma (IFN-G) that 
makes macrophages able to destroy captured viral particles and 
allow them to release IL-12 that promotes immune system 
activation against the virus. Th1 cells allow the differentiation 
and the iso-switching B cells into immunoglobulins class G 
(IgG) producing plasma cells. IgG are specific antibodies that 
bind against virus receptors, eventually inhibiting its capacity 
to infect cells. MHC-I/peptides DC presenting cells are also 
able to activate CD8 cytotoxic T cells (Tc) to destroy SARS-
CoV-2 infected cells and then eliminate the reservoir of 
infection. Eventually, Tc migrate into the site of infection and 
recognize and kill infected LEP. Tc killed infected LEP release 
chemokines and interleukin 1 and 6 (IL-1 and IL-6). IL-1 is the 
main cytokine that induces several systemic effects in the host, 
for example fever. IL-6 is a proinflammatory cytokine that can 
change the severity of COVID-19 disease as reported in very 
recent literature [47]. Our disease model takes good account of 
the cytokines storm in the prognosis of the severity of the 
disease. Entities (both cellular and molecular) move and diffuse 
in a simulation space represented as a L X L lattice (L is set 
depending on the dimension of the compartment one intends to 
reproduce), with periodic boundary conditions. There is no 
correlation between entities residing on different sites at a fixed 
time as the interactions among cells and molecules take place 
within a lattice-site in a single time step. All entities are allowed 
to move with a uniform probability between neighboring 
lattices in the grid and with an equal diffusion coefficient 
(Brownian motion).  
III. RESULTS AND DISCUSSION 
A. Tuning and validation of SARS-CoV-2 disease model 
Scientific knowledge about SARS-CoV-2 is still not complete 
and research contributions appear every day. Apart from this, 
we used all the available literature data to compare the 
dynamics predicted by the UISS platform with all findings we 
were able to fetch. The first task we accomplished with success 
was the evaluation of the replication kinetic of SARS-CoV-2. 
To this end, we set a first use case simulation considering a 
digital patient in which a virus challenge dose of 0.1 
multiplicity of infection (MOI) was administered at day 0. 
 
 
Fig. 2.  In silico SARS-CoV-2 viral dynamics and related CPE in a mild to 
moderate scenario. In the left panel, one can observe the mild digital patient 
case in which a virus challenge dose of 0.1 multiplicity of infection (MOI) was 
administered at day 0 (green line). Peak viral titers are reached by 48 h post-
inoculation. IL-6 dynamics and its related plasma levels (fg/µL) are also shown 
in the inner panel (purple line). In the right one, the dynamics of CPE on the 
lung infected cells is measured: they started at day 3.5 and peak around day 5. 
After 21 days, the simulated digital patient almost recovers from the infection. 
One can notice how UISS is capable to simulate, accordingly to the recent 
literature, the early viral clearance by day 10 post-onset in mild cases. 
 
  
 
 
Fig. 3.  In silico SARS-CoV-2 viral dynamics and related CPE in a severe 
scenario. In the left panel, one can observe the severe digital patient case in 
which a virus challenge dose of 0.1 multiplicity of infection (MOI) was 
administered at day 0 (green line). Peak viral titers are reached by 48 h post-
inoculation. In addition, it is wort to note that virus persists after day 10, until 
day 15, and its complete clearance is around day 19. In the inner panel (purple 
line), IL-6 dynamics and its related plasma levels (fg/µL) are shown. IL-6 
dynamics shows a much more prominent peak of values. This is in very good 
agreement with latest literature data, as explained within the manuscript. In the 
right panel, the dynamics of CPE on the lung infected cells is measured: in this 
case, CPE are much more severe and the recover from infection is clearly 
delayed. UISS is capable to simulate, accordingly to the recent literature, how 
the severe cases tend to have a higher viral load both at the beginning and later 
on.  
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Simulation space was 5 cubic millimeters of lung tissue, 5 cubic 
millimeters of lymph tissue and 5 microliters of peripheral 
blood. Figure 2 (right panel) shows that peak viral titers are 
reached by 48 h post-inoculation. We also plotted IL-6 
dynamics: as reported in [9] the levels of IL-6 could be provide 
a prognosis on the severity of the infection.  
We also measured cytopathic effects (CPE) on the lung 
compartment. CPE are defined as changes occurred in the 
infected cell that eventually lead its lysis or inability to 
reproduce. Figure 2 (left panel) highlights the dynamics of 
CPE: they started at day 3.5 and peak around day 5. After 21 
days, the simulated digital patient almost recovers from the 
infections. These findings are in good agreement with actual 
literature [13], [48].  
In a recent work, Liu et al [49] reported that mild cases were 
found to have an early viral clearance, with 90% of these 
patients repeatedly testing negative by day 10 post-onset. At the 
same time, they found that all severe cases still tested positive 
at or beyond day 10 post-onset. Moreover, severe cases tended 
to have a higher viral load both at the beginning and later. In 
contrast, mild cases had early viral clearance 10 days post on-
set. UISS was also able to reproduce this scenario. As one can 
see, Figure 2 is in very good agreement for viral clearance.  
 
We also were able to reproduce severe conditions acting on the 
immune system aging parameters obtaining results showed in 
Figure 3. In this case, Figure 3 (right panel) shows virus 
presence after day 10, until day 15, and its complete clearance 
about day 19. Moreover, CPE are much more severe and the 
recover from infection was clearly delayed (left panel). IL-6 
dynamics shows a much more prominent peak of values. This 
is in very good agreement with latest literature data, as 
explained before.  
To validate the main immune system response of mild-to-
moderate COVID-19 patients, we used the results available in 
[50]. In this work, the authors report the kinetics of immune 
responses in terms of activated CD4+ T cells, CD8+ T cells, IgM 
and IgG antibodies, detected in blood before symptomatic 
recovery. As one can see from Figure 4, the kinetics of activated 
Th1 cells (panel A), activated CD8 T cells (panel B) and the 
IgM and IgG (panel C) predicted by the simulator are in good 
agreement with their findings.  
B. UISS IST to predict mAb efficacy against SARS-CoV-2 
UISS is an immune system simulation platform that was 
designed to be applied to several and different scenarios, 
especially to carry on in silico trials to predict the efficacy of a 
specific prophylactic or therapeutic vaccine against a particular 
disease. In silico trials aim to strongly reduce the time to 
develop new effective therapeutics: this is particularly crucial 
in situation like the one we are facing with. As soon as a disease 
model incorporated into UISS is tuned and validated against 
available data, it can be used as an in silico lab to test new 
vaccines. In the previous section, we demonstrated that UISS-
SARS-CoV-2 is able to reproduce and predict the main aspects 
of the viral infection. As a working example, here we show how 
the platform can be immediately used to predict the efficacy of 
a human monoclonal antibody that neutralizes SARS-CoV-2 
developed by Wang et al. [32]. In this work the authors suppose 
that the developed antibody (named 47D11) neutralizes SARS-
CoV-2 through a yet unknown mechanism that is different from 
receptor binding interference. Hence, in implementing the 
mechanism of action of 47D11 into UISS computational 
framework we used the alternative mechanisms of coronavirus 
neutralization by receptor-binding domain (RBD) targeting 
antibodies that have been reported, including spike inactivation 
through antibody-induced destabilization of its prefusion 
structure, which Wang et al. indicated also applicable for 
47D11. We then modeled the receptor interaction to 
trigger irreversible conformational changes in coronavirus 
spike proteins enabling membrane fusion, as described in [51]. 
The validation in silico trial consists in simulating the in vitro 
experiment conducted by Wang et al. where they showed that 
the monoclonal antibody was effective in contrasting SARS-
CoV-2 to infect the target cells. To mimic the in vitro system 
that is an isolated system, we disabled both the lung and the 
 
 
Fig. 5. Antibody-mediated neutralization of SARS-CoV-2 infection on 
simulated lung epithelial cells. 10ng/ml revealed the best concentration to obtain 
maximum clearance of the virus. 
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Fig. 4.  Cellular and humoral response mounted by the host immune system 
against SARS-CoV-2. Panel A shows the dynamics of CD4+T cells, subtype 1 
(Th1). Th1 are primed by dendritic cells that present the viral particles 
complexed with MHC-II of the host. Th1 cells help the activation of B cells, 
eventually favoring their iso-type switching to IgG producing plasma cell. B 
cells dynamics is depicted in panel B. Antigen activated B cells initially 
releases IgM; then, after interacting with Th1 and their released pro-
inflammatory cytokines, they start to release specific IgG directed against 
SARS-CoV-2 virus. 
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lymph node compartments and we turned off all the immune 
system interactions in UISS. We then injected virus particles in 
the peripheral blood compartment of the simulator along with 
different concentrations of mAb. Only LEP-SARS-CoV-2 
interaction has been allowed to happen. Figure 5 shows the 
obtained results.  
As one can envisage from the figure, we reproduced with great 
accuracy the in vitro results reported by Wang et al. In 
particular, the computational framework was able to correctly 
predict the efficacy of 47D11 mAb simulating its mechanism of 
action that induces the entering of the virus inside LEP. The 
most effective concentration is 10 ng/ml. This step makes the 
simulation platform ready for usage as a in silico trial to predict 
now the effects of a mAb therapy. For this purpose, we designed 
two kind of in silico experiments. The first one dealt with mAb 
vaccination strategy used to prevent the onset of infection. The 
second one involved mAb as interventional drug to treat already 
infected hosts. 
1) mAb as a preventive vaccine  
Figure 6 depicts the dynamics of LEP while we injected the 
47D11 mAb at day 1 at a concentration of 10ng/ml. 
Subsequently, we injected SARS-CoV-2 virus particles at day 
7 (panel A), day 14 (panel B), month 1 (panel C), month 3 
(panel D), month 6 (panel E) and after 1 year (panel F). Solid 
lines refer to the no-treated digital patient while dashed lines 
refer to mAb treated one. Blue lines depict actively infected 
LEP while red lines represent LEP to show the CPE.  
Panel A of figure 6 clearly demonstrates that if a patient enters 
in contact with the virus just after 7 days post vaccination, he is 
fully protected from the infection: as one can see, SARS-CoV-
2 actively infected values of LEP are low. This is also true if a 
potential subject is being infected after two weeks (panel B), 
one month (panel C) or three months (panel D) after 
vaccination. Things change for the other two cases i.e., panel E 
(subject infected after 6 months) or panel F (subject infected 
after one year). In this circumstance, the computational 
framework predicts that the mAb vaccination is practically 
ineffective in protecting the onset of the disease. A second 
injection of the mAb is suggested around month 4 to extend the 
protection of the host for one year.  
 
2) mAb as a therapeutic vaccine 
The second experiment we designed is to use our in silico trial 
platform to predict the efficacy of a mAb-based vaccine in 
therapeutic settings. We envisaged both mild-moderate case 
(the same digital patient type shown in Figure 2) and severe 
case (the same digital patient shown in Figure 3). For both 
cases, we administered the mAb vaccine one day and two days 
after the onset of infection. Figure 7 shows different behavior 
for both mild-moderate case (panel A, mAb injected one day 
after the onset of infection, and panel B, mAb injected two days 
after the onset of infection) and severe case (panels C, mAb 
injected one day after the onset of infection, and panel D, mAb 
injected two days after the onset of infection). As Figure 7 
depicts, mAb vaccine is effective in preventing or strongly 
limiting the CPE. If the mAb vaccine is injected after two days, 
it is not able to protect the LPE of the host to be infected by the 
virus and consequently from COVID-19 pathology.  
IV. CONCLUSIONS 
In this paper, we present an in silico platform that was 
demonstrated able to reproduce the main dynamics of SARS-
CoV-2 virus and the elicited host immune response against it. 
The disease model was implemented inside UISS 
 
 
 
 
Fig. 6. In silico trial of 47D11 to predict preventive efficacy. The overall 
prediction dynamics of LEP at the injection time of 47D11 mAb (day 1) at a 
concentration of 10ng/ml after different SARS-CoV-2 challenge in time (panels 
A to F) is depicted. Specifically, one can observe the exposures at virus particles 
at day 7 (panel A), day 14 (panel B), month 1 (panel C), month 3 (panel D), 
month 6 (panel E) and after 1 year (panel F). Solid lines refer to the no-treated 
digital patient while dashed lines refer to mAb treated one. Blue lines depict 
actively infected LEP while red lines represent LEP to show the CPE. Panel A 
highlights that if a patient enters in contact with the virus just after 7 days post 
vaccination, he is fully protected from the infection (SARS-CoV-2 actively 
infected values of LEP are low). This is also true if a potential subject is being 
infected after two weeks (panel B), one month (panel C) or three months (panel 
D) after vaccination. Oppositely, in panel E (subject infected after 6 months) and 
panel F (subject infected after one year) mAb vaccination is practically 
ineffective in protecting the onset of the disease. 
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Fig. 7.  In silico trial of 47D11 to predict therapeutic efficacy. Different 
behaviors for both mild-moderate case (panels A and B) and severe case 
(panels C and D) are shown. In panel A, mAb is injected one day after the 
onset of infection. In panel B, mAb is injected two days after the onset of 
infection. In panel C, mAb is injected one day after the onset of infection. 
In panel D, mAb is injected two days after the onset of infection. Blue lines 
depict actively infected LEP while red lines represent LEP to show the CPE. 
As one can notice, mAb vaccine is effective in preventing or strongly 
limiting the CPE only by two days of the infection. 
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computational framework, an in silico trial platform that has 
been applied to several biological scenario. UISS shows that the 
simulated SARS-CoV-2 dynamics is in very good agreement 
with the one described in the latest literature; also, the immune 
system response predicted by UISS against the virus mirrored 
the one observed in state of the art research data. This validation 
step entitled UISS-SARS-CoV-2 to be used as a in silico lab to 
test the efficacy of potential vaccines for COVID-19, knowing 
a priori their mechanism of action. Hence, we set an in silico 
trial to test a recent vaccination strategy based on the 
employment of monoclonal antibodies directed against a 
specific target protein of the virus. The simulator is in good 
agreement in predicting the in vitro experiment outcome 
performed by the inventors of 47D11 mAb. Finally, we 
designed two experimental settings to predict the efficacy of 
mAb vaccination when used in both preventive and therapeutic 
cases. We predicted that mAb is an effective therapy when used 
as a preventive vaccine (granting up one year protection when 
injected with a two times schedule). Moreover, we envisaged 
that 47D11 mAb if effective only if administered in a very 
stringent time-frame if employed as a therapeutic strategy. 
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